GlassScriptPhysician profile
Nicole A Bell
NPI 1255404380
$3,901.86
in general payments reported to CMS, 2019-2025
30 companies · $6.01 in 2025
The $6.01 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $510 · 2020: $309 · 2021: $1,066 · 2022: $849 · 2023: $866 · 2024: $295 · 2025: $6.01.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,167.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celularity INC. | $600.00 | 2021 | |
| Abbvie INC. | $584.80 | 2019-2023 | Liletta, Lo Loestrin Fe |
| Myovant Sciences INC. | $421.55 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $338.25 | 2023-2024 | Myfembree |
| Astellas Pharma US INC | $182.02 | 2023-2024 | Veozah |
| Coopersurgical, INC. | $165.84 | 2019-2024 | Paragard T 380a |
| Exeltis, USA INC. | $163.76 | 2019-2024 | Slynd |
| Organon LLC | $159.28 | 2021-2024 | Nexplanon |
| Lupin INC. | $157.41 | 2019-2021 | |
| Therapeuticsmd, INC. | $139.90 | 2019-2020 | |
| Avion Pharmaceuticals | $124.04 | 2019-2023 | Balcoltra |
| Daiichi Sankyo INC. | $122.72 | 2021-2024 | Injectafer |
| Evofem Biosciences, INC. | $115.78 | 2021-2024 | Phexxi |
| Scynexis, INC. | $92.91 | 2022 | |
| Mayne Pharma Commercial LLC | $86.97 | 2023-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $53.56 | 2019 | |
| Biogen, INC. | $49.17 | 2024 | |
| Agile Therapeutics, INC. | $44.00 | 2021-2023 | Twirla |
| Alexion Pharmaceuticals, INC. | $39.00 | 2022-2023 | Ultomiris |
| Aspira Women'S Health INC | $37.29 | 2021 | |
| Duchesnay USA Incorporated | $33.60 | 2019 | |
| Merck Sharp & Dohme LLC | $32.41 | 2019-2020 | |
| Genzyme Corporation | $24.46 | 2021 | |
| Ethicon US, LLC | $21.55 | 2022 | |
| Hologic Sales and Service, LLC | $20.76 | 2023 | Aptima |
| Bayer Healthcare Pharmaceuticals INC. | $20.70 | 2023 | |
| Allergan, INC. | $20.58 | 2019 | |
| Optumhealth Care Solutions, LLC | $18.80 | 2023 | Vivify Health Care Team Portal |
| Olympus America INC. | $17.57 | 2019 | |
| Mission Pharmacal Company | $13.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.